Official tally deems Forest proxy-fight winner; Will private equity grab PharMerica from Omnicare?;

@FiercePharma: Sanofi could kill two birds with one stone with buyout of India's Universal Medicare. 1. Emerging markets. 2. OTC brands. Story | Follow @FiercePharma

> It's official: Forest Laboratories ($FRX) shareholders chose the company's board nominees over the slate proposed by activist investor Carl Icahn, ending the proxy fight in a loss for the challengers. Release

> PharMerica ($PMC) isn't impressed by Omnicare's ($OCR) $15-per-share buyout bid; analysts figure private equity may swoop in with a higher offer. Report

> Afexa Life Sciences reaffirmed its rejection of a hostile takeover bid from Paladin Labs. Article

> Researchers didn't find a major heart risk with new psoriasis drugs, but say more study is needed to make sure. Piece

> Zacks put Onyx Pharmaceuticals on its "strong sell" list after Q2 losses came in wider than the average forecast. News

> Growing business from Chinese clients pushed ShangPharma's sales up, helping the research services firm diversify away from multinationals. Report

Biotech News

@FierceBiotech: Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful Alpharadin for prostate cancer. Item | Follow @FierceBiotech

@JohnCFierce: NIH conflict rules for researchers. Researchers have to notify at $5K, but people have to ask to see it. No public site. That's a mistake. | Follow @JohnCFierce

@RyanMFierce: Samsung entering the genomic analysis fray with cloud-based service, free pilot phase from Sept. to Nov. News | Follow @RyanMFierce

@MaureenFierce: "Unabomber Copycat" Group Threatens Nanotechnology Researchers. Piece | Follow @MaureenFierce

> Peregrine shares spike on Ph2 cancer data. Report

> Boehringer Ingelheim gets the dirt flying on $42.5M R&D facility. More

> SurModics slashes delivery tech workforce, closes plant in restructuring. Story

> Docs wary of any biosimilars that lack compelling data. Article

> NIH 's final conflict rules for researchers spur new controversy. Details

> United vows to file NDA on PAH drug after it flunks Ph3. News

Drug Delivery News

> Unilife boasts 'world's first' safety mechanism in multi-chamber syringe. More

> Alkermes stock upgrade validates drug delivery focus. News

> New nasal delivery method may offer faster, better pain relief. Report

> Drug-delivery company SurModics cuts 9% of workforce after J&J loss. Story

> Echo Therapeutics video shows pain-free skin prep. Details

> Microwaves get bacteria to open sesame. Article

Medical Device News

> Occlutech reports closing of $21.6M financing. More

> Thermo Fisher wraps up Phadia buy. Report

> Aethlon, Sarcoma Oncology Center to study hemopurifier in cancer patients. Article

> GE lays off 81 in Milwaukee. Story

> SurModics cutting 9% of workforce in realignment. News

> Medtronic sees net earnings slide 1% in Q1. Details

And Finally... New narcolepsy cases tripled in China after the swine flu pandemic, but not because of vaccines, study finds. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.